|Bid||215.04 x 800|
|Ask||215.08 x 1000|
|Day's range||214.63 - 215.13|
|52-week range||67.98 - 217.50|
|Beta (5Y monthly)||2.00|
|PE ratio (TTM)||N/A|
|Earnings date||10 May 2021 - 14 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||204.90|
Shares of GW Pharmaceuticals (NASDAQ: GWPH) rose 40.5% in February, according to data provided by S&P Global Market Intelligence. The bulk of the move came on Feb. 3 when Jazz Pharmaceuticals (NASDAQ: JAZZ) announced it would be purchasing GW for $7.2 billion, or the equivalent of $220 per share, made up of $200 per share in cash and $20 in Jazz stock. GW has the only drug made from cannabis, the emerging blockbuster Epidiolex.
Marijuana will provide the basis for many of tomorrow's blockbuster drugs. David Borun shows you how to invest in this burgeoning industry.
Following a more than one-year downtrend, there's no longer any doubt about it: Marijuana stocks are back in a big way. The excitement surrounding pot stocks was readily evident when analyzing their monthly returns in February. Whereas the benchmark S&P 500 ended last month higher by 2.6%, 10 marijuana stocks crossed the finish line with a gain of at least 20%.